All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/adv melanoma (mML), pembrolizumab (10mg/kg) vs. anti-CTLA-4, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
0.69 [0.52 ; 0.91 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.53 ; 0.87 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable PFS (extension)detailed results KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.50 ; 0.75 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.58 [0.47 ; 0.72 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable objective responses (ORR)detailed results KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
3.63 [2.34 ; 5.65 ] KEYNOTE-006 (3 week), 2015 1 0% 555 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.63 [0.39 ; 1.03 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE (any grade)detailed results KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
1.16 [0.78 ; 1.72 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
0.82 [0.53 ; 1.28 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.23 [0.69 ; 2.18 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.23 [0.01 ; 5.12 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
0.34 [0.14 ; 0.83 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
0.39 [0.10 ; 1.52 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.92 [0.06 ; 14.85 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.92 [0.18 ; 4.62 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
4.69 [0.54 ; 40.40 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.46 [0.04 ; 5.11 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.46 [0.04 ; 5.11 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.46 [0.04 ; 5.11 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.92 [0.06 ; 14.85 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.92 [0.06 ; 14.85 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.02 ; 46.74 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.02 ; 13.80 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 16:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 575
